Terms: = Leukemia AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Clinical Outcome
26 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Immune Surveillance of Acute Myeloid leukemia Is Mediated by HLA-Presented Antigens on leukemia Progenitor Cells.
Nelde A; Schuster H; Heitmann JS; Bauer J; Maringer Y; Zwick M; Volkmer JP; Chen JY; Stanger AMP; Lehmann A; Appiah B; Märklin M; Rücker-Braun E; Salih HR; Roerden M; Schroeder SM; Häring MF; Schlosser A; Schetelig J; Schmitz M; Boerries M; Köhler N; Lengerke C; Majeti R; Weissman IL; Rammensee HG; Walz JS
Blood Cancer Discov; 2023 Nov; 4(6):468-489. PubMed ID: 37847741
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Polymorphism Study of idh 1/2 and TET2 Genes in Acute Myeloid leukemia Patients.
Atef M; Shafik NF; H A Hassan N; Allam RM; El-Meligui YM; Abdelaziz H
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3169-3182. PubMed ID: 37774069
[TBL] [Abstract] [Full Text] [Related]
4. Reductive TCA cycle catalyzed by wild-type idh2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
[TBL] [Abstract] [Full Text] [Related]
5. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and idh1/2 mutations.
Yasuda T; Sanada M; Kawazu M; Kojima S; Tsuzuki S; Ueno H; Iwamoto E; Iijima-Yamashita Y; Yamada T; Kanamori T; Nishimura R; Kuwatsuka Y; Takada S; Tanaka M; Ota S; Dobashi N; Yamazaki E; Hirose A; Murayama T; Sumi M; Sato S; Tange N; Nakamura Y; Katsuoka Y; Sakaida E; Kawamata T; Iida H; Shiraishi Y; Nannya Y; Ogawa S; Taniwaki M; Asou N; Hatta Y; Kiyoi H; Matsumura I; Horibe K; Mano H; Naoe T; Miyazaki Y; Hayakawa F
Blood; 2022 Mar; 139(12):1850-1862. PubMed ID: 34695176
[TBL] [Abstract] [Full Text] [Related]
6. Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia.
Wang B; Guan W; Lv N; Li T; Yu F; Huang Y; Wang Y; Li L; Yu L
Hematology; 2021 Dec; 26(1):371-379. PubMed ID: 33971800
[TBL] [Abstract] [Full Text] [Related]
7. Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid leukemia.
Bhatnagar B; Kohlschmidt J; Mrózek K; Zhao Q; Fisher JL; Nicolet D; Walker CJ; Mims AS; Oakes C; Giacopelli B; Orwick S; Boateng I; Blachly JS; Maharry SE; Carroll AJ; Powell BL; Kolitz JE; Stone RM; Byrd JC; Paskett ED; de la Chapelle A; Garzon R; Eisfeld AK
Cancer Discov; 2021 Mar; 11(3):626-637. PubMed ID: 33277314
[TBL] [Abstract] [Full Text] [Related]
8. Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse.
Onecha E; Rapado I; Luz Morales M; Carreño-Tarragona G; Martinez-Sanchez P; Gutierrez X; Sáchez Pina JM; Linares M; Gallardo M; Martinez-López J; Ayala R
Haematologica; 2021 Sep; 106(9):2325-2333. PubMed ID: 32732356
[TBL] [Abstract] [Full Text] [Related]
9. Allogeneic Hematopoietic Cell Transplantation outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.
Salhotra A; Afkhami M; Yang D; Mokhtari S; Telatar M; Gu D; Pillai RK; Weisenburger DD; Murata-Collins J; Weigel D; Aoun P; Aldoss I; Al Malki MM; Khaled S; Mei M; Ali H; Aribi A; Budde E; Sandhu K; O'Donnell M; Snyder D; Pullarkat V; Forman SJ; Marcucci G; Nakamura R; Stein A
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e400-e405. PubMed ID: 31155409
[TBL] [Abstract] [Full Text] [Related]
10. Down-regulation of pseudogene Vimentin 2p is associated with poor outcome in de novo acute myeloid leukemia.
Zhai LL; Zhou J; Zhang J; Tang X; Zhou LY; Yin JY; Vanessa MD; Peng W; Lin J; Deng ZQ
Cancer Biomark; 2017; 18(3):305-312. PubMed ID: 28106537
[TBL] [Abstract] [Full Text] [Related]
11. Mutant idh: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.
Garrett-Bakelman FE; Melnick AM
Epigenomics; 2016 Jul; 8(7):945-57. PubMed ID: 27431380
[TBL] [Abstract] [Full Text] [Related]
12. Characteristics, clinical outcome, and prognostic significance of idh mutations in AML.
DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
[TBL] [Abstract] [Full Text] [Related]
13. High idh1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia.
Ma QL; Wang JH; Wang YG; Hu C; Mu QT; Yu MX; Wang L; Wang DM; Yang M; Yin XF; Chen FF; Lu SS; Chen J; Zhu ZJ; Chen SJ; Jin J
Int J Cancer; 2015 Sep; 137(5):1058-65. PubMed ID: 25523507
[TBL] [Abstract] [Full Text] [Related]
14. idh mutation in glioma: new insights and promises for the future.
Turkalp Z; Karamchandani J; Das S
JAMA Neurol; 2014 Oct; 71(10):1319-25. PubMed ID: 25155243
[TBL] [Abstract] [Full Text] [Related]
15. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
Iqbal J; Wright G; Wang C; Rosenwald A; Gascoyne RD; Weisenburger DD; Greiner TC; Smith L; Guo S; Wilcox RA; Teh BT; Lim ST; Tan SY; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Tubbs RR; Ott G; Geissinger E; Gaulard P; Piccaluga PP; Pileri SA; Au WY; Nakamura S; Seto M; Berger F; de Leval L; Connors JM; Armitage J; Vose J; Chan WC; Staudt LM;
Blood; 2014 May; 123(19):2915-23. PubMed ID: 24632715
[TBL] [Abstract] [Full Text] [Related]
16. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract] [Full Text] [Related]
17. [Research on molecular markers for epigenetic changes in myeloid malignancies].
Li L; Sun XM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
[TBL] [Abstract] [Full Text] [Related]
18. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
[TBL] [Abstract] [Full Text] [Related]
19. Isocitrate dehydrogenase mutations in leukemia.
McKenney AS; Levine RL
J Clin Invest; 2013 Sep; 123(9):3672-7. PubMed ID: 23999441
[TBL] [Abstract] [Full Text] [Related]
20. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.
Hou HA; Lin CC; Chou WC; Liu CY; Chen CY; Tang JL; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Kuo YY; Lee MC; Liu MC; Liu CW; Lin LI; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Leukemia; 2014 Jan; 28(1):50-8. PubMed ID: 23929217
[TBL] [Abstract] [Full Text] [Related]
[Next]
